On January 5, Insilicon announced a multi-year collaboration with Servier to develop anti-tumor drugs.

Under the agreement, InSilicon Technologies combines its AI-driven drug discovery platform with Servier's expertise in anti-tumor drug development, focusing on the research and development of such drugs. Servier will pay a $32 million upfront payment and recent research milestones, bringing the total agreement value to $888 million. Servier will share the research and development costs and, after nominating a drug candidate, will lead subsequent clinical development, regulatory communications, and commercialization.

Founded in 2014, Insil Intelligence is an AI-driven biopharmaceutical company that has built a rich pipeline of innovative research and development over the past 11 years. Its first pipeline, a TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), has been included in the Breakthrough Therapy Programme. Subsequent pipeline projects include a USP1 inhibitor, a KAT6 inhibitor, and a TEAD inhibitor.

In conclusion , on December 30, 2025, InSilicon Technologies was listed on the Hong Kong Stock Exchange, becoming the first AI pharmaceutical company to list under Rule 8.05 of the Main Board Listing Rules. InSilicon Technologies raised HK$2.277 billion in its IPO, making it the highest-funded Hong Kong biopharmaceutical IPO this year, marking the beginning of a new stage of development. This licensing partnership with Servier signifies further recognition of its AI pharmaceutical technology platform by multinational pharmaceutical companies.

https://news.yaozh.com/archive/46825.html